Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,528.8
41.2 (1.66%)

 

  • STI Straits Times Index
    2,528.8
    41.2 (1.66%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,343.1
    15.0 (1.13%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,484.3
    131.9 (0.56%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,772.2
    7.3 (0.26%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    19,389.4
    724.8 (3.88%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,545.6
    206.7 (4.76%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,154.6M
  • Value: 1,885.1M
  • Rise: 274
  • Fall: 88
  • Unch: 450

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Genting Sing0.665+0.050
Singtel2.570+0.050
ThaiBev0.610+0.015
Mapletree Log Tr1.600+0.060
Rex Intl0.090+0.001
ESR-REIT0.320+0.010
YZJ Shipbldg SGD0.850+0.020
NetLink NBN Tr0.885-0.015
Ascendas Reit2.780+0.110
Medtecs Intl0.074+0.003

World Indices

World Indices
Name Last Change
Nasdaq 7,502.4 -295.2
HSI 23,484.3 +131.9
HSCEI 9,504.9 +57.4
Jakarta 4,545.6 +206.7
Nikkei 225 19,389.4 +724.8
SSE Comp 2,772.2 +7.3
Shanghai A 2,905.2 +7.7
Shanghai B 218.9 -0.2
KOSPI 1,717.7 +31.5

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CELYAD ADS EACH REPR 1 ORD CELYAD ADS EACH REPR 1 ORD
Updated on 27 Mar 2020 (End of trading day)
Last (USD): 8.070 Change: +0.460 High: 8.760 Remarks: -
Change (%): +6.04 Low: 7.250
Open 7.570 Yesterday's Close 7.61
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 9,098 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.16701 Trailing EPS (USD) e -2.30141 NAV (USD) b 2.3339
PE a - Trailing PE f - Price / NAV b 3.4577
Dividend (USD) d - Cash In Hand (USD) g 3.1672 Issued & Paid-up Shares c 13,942,000
Dividend Yield (%) d - Price / Cash In Hand g 2.548 Treasury Shares h -
Beta - 75 Daysi 1.198 R-Squared - 75 Days(%)i 17.40 Market Cap (M) 112.512
Beta - 500 Daysi 0.487 R-Squared - 500 Days (%)i 1.95 Enterprise Value (M) 91.920
Piotroski F Score 3 Exchange Code CYAD Par Value ( $ ) n.a.
52 Weeks Volatility (%) 94.23 Free Float (%) -
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 18 Sep 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 17 Sep 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CELYAD ADS EACH REPR 1 ORD NASDAQ 112.512 - - 3.4577 -
Industry Biotechnology NASDAQ 2,196.951 250.798 231.590 5.3101 0.832
Local Peer AMGEN INC NASDAQ 116,941.034 13.932 14.912 12.0894 2.843
Local Peer GILEAD SCIENCES INC NASDAQ 92,056.174 16.876 17.092 4.0868 3.175
Local Peer VERTEX PHARMACEUTICAL NASDAQ 56,323.598 26.867 47.861 9.2558 -
Local Peer BIOGEN INC NASDAQ 51,653.492 11.658 8.772 3.8711 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 49,456.177 20.232 23.375 4.4596 -
Local Peer ILLUMINA INC NASDAQ 39,550.350 47.882 39.471 8.5737 -
Local Peer SEATTLE GENETICS INC NASDAQ 18,822.850 - - 10.0319 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 18,599.898 239.686 7.736 1.6501 -
Local Peer INCYTE CORPORATION NASDAQ 14,948.873 136.527 33.450 5.7531 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 14,281.984 - - 4.5741 -
Local Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 12,472.900 - - 28.4856 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 11,806.133 - 38.040 4.2714 -
Other Local Peers ALNYLAM PHARMACEUTICALS INC (NASDAQ), MODERNA INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), VIELA BIO INC (NASDAQ), ALECTOR INC (NASDAQ), EPIZYME INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), XENCOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), INSMED INC (NASDAQ), ARVINAS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), REGENXBIO INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VERACYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), NEXTCURE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), NOVAVAX INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), IMMUNOGEN INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), RETROPHIN INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), PASSAGE BIO INC (NASDAQ), COMPUGEN (NASDAQ), AVROBIO INC (NASDAQ), PRECIGEN INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ARDELYX INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), VERASTEM INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), ANAPTYSBIO INC (NASDAQ), AGENUS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), UROGEN PHARMA LTD (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MERUS B V (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CUE BIOPHARMA INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), NANTKWEST INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), KAMADA (NASDAQ), SERES THERAPEUTICS (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), PERSONALIS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), VBI VACCINES INC CDA (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), RECRO PHARMA INC (NASDAQ), CHIASMA INC (NASDAQ), MEDICINOVA INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), VAXART INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), AFFIMED N V (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), INFLARX N V (NASDAQ), CHIMERIX INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VERMILLION INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ARAVIVE INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), IMV INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), LUMOS PHARMA INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), VACCINEX INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), OTONOMY INC (NASDAQ), COHBAR INC (NASDAQ), SESEN BIO INC (NASDAQ), ORGENESIS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SYNLOGIC INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), TREVENA INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), EQUILLIUM INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), RESTORBIO INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ADVAXIS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), TOCAGEN INC (NASDAQ), ATYR PHARMA INC (NASDAQ), ZAFGEN INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), EVOGENE LTD (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIOCARDIA INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), BIONANO GENOMICS INC (NASDAQ), OCUGEN INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), AIKIDO PHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), PRECIPIO INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENESTECH INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ)
Global Peer CSL ASX 126,734.157 47.237 43.750 14.6540 0.950
Global Peer AMGEN-T HKEx 589,807.000 8.965 9.598 7.8255 4.417
Global Peer AGILENT TECHNOLOGIES INC NYSE 21,957.352 69.486 28.740 4.5292 0.863
Global Peer SINO BIOPHARM HKEx 133,071.382 12.419 12.889 3.9630 0.692
Global Peer WUXI BIO HKEx 128,585.032 172.156 247.185 - -
Global Peer BEIGENE HKEx 77,435.385 - - 10.3285 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 22,324.552 134.254 - 6.2955 -
Global Peer 3SBIO HKEx 21,259.549 14.054 17.105 2.0954 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,663.440 42.479 48.781 2.4469 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), FRONTAGE (HKEx), VIVA BIOTECH (HKEx), MYOVANT SCIENCES LTD (NYSE), KADMON HLDGS INC (NYSE), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD (ASX), ARCUS BIOSCIENCES INC (NYSE), ASCENTAGE-B (HKEx), ASCLETIS-B (HKEx), MESOBLAST LTD (ASX), SINOMAB BIO-B (HKEx), NANOVIRICIDES INC (NYSE American), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), BBI LIFE SCI (HKEx), DPHARMA (Bursa), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), UNI-BIO GROUP (HKEx), NEXT SCIENCE LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), ENZO BIOCHEM INC (NYSE), CEL-SCI CORP (NYSE American), IBIO INC (NYSE American), 22ND CENTURY GROUP INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), AIM IMMUNOTECH INC (NYSE American), IMUGENE LIMITED (ASX), CT ENTERPRISE (HKEx), SYNTHETIC BIOLOGICS INC (NYSE American), CYNATA THERAPEUTICS LTD (ASX), BIOSINO BIO-TEC (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), BIOTRON (ASX), ORAGENICS INC (NYSE American), IMMUTEP LTD (ASX), INVEX THERAPEUTICS LTD NPV (ASX), KAZIA THERAPEUTICS LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), MEMPHASYS LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), REGENT PACIFIC (HKEx), ACTINIUM PHARMACEUTICALS INC (NYSE American), ANTEOTECH LIMITED (ASX), Suntar Eco-City^ (SGX), ACTINOGEN MEDICAL LTD (ASX), GENETIC TECHNOLOGIES (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), REGENEUS LTD (ASX), CCP TECHNOLOGIES LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), BIONOMICS LTD (ASX), HAO WEN HLDGS (HKEx), PATRYS LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), RHINOMED LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), BENITEC BIOPHARMA LTD (ASX), ADALTA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), LEAF RESOURCES LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), CRYOSITE (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+2.030
+33.61 %
10 Days -+1.675
+26.19 %
20 Days --0.320
-3.81 %
Medium Term Return 3 Months --2.220
-21.57 %
6 Months --1.530
-15.94 %
1 Year --12.330
-60.44 %
Long Term Return 2 Years --26.930
-76.94 %
3 Years --18.130
-69.20 %
Annualised Return Annualised --
-32.47 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 4.100 - 22.860 Change From 1 Year Low +3.970 % Change From 1 Year Low (%) +96.83
Change From 1 Year High -14.790 % Change From 1 Year High (%) -64.70
2 Years Range 4.100 - 37.200 Change From 2 Years Low +3.970 % Change From 2 Years Low (%) +96.83
Change From 2 Years High -29.130 % Change From 2 Years High (%) -78.31
5 Years Range 4.100 - 64.750 Change From 5 Years Low +3.970 % Change From 5 Years Low (%) +96.83
Change From 5 Years High -56.680 % Change From 5 Years High (%) -87.54
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Celyad SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Historical Price Data

Date Open High Low Close Volume VWAP
27 Mar 2020 7.570 8.760 7.250 8.070 9,098 -
26 Mar 2020 7.560 8.000 7.220 7.610 12,302 -
25 Mar 2020 6.490 8.000 6.250 8.000 20,380 -
24 Mar 2020 5.500 6.840 5.500 5.740 7,432 -
23 Mar 2020 5.845 5.845 5.030 5.030 3,561 -
20 Mar 2020 5.000 6.800 5.000 6.040 16,080 -
19 Mar 2020 7.280 7.280 4.490 4.720 10,896 -
18 Mar 2020 5.010 6.160 4.100 4.640 9,348 -
17 Mar 2020 5.000 5.310 4.700 5.000 26,248 -
16 Mar 2020 5.625 6.010 4.160 4.180 84,525 -
13 Mar 2020 7.010 7.080 5.900 6.395 6,314 -
12 Mar 2020 7.050 7.090 6.310 6.655 23,689 -
11 Mar 2020 8.200 8.300 7.750 8.270 5,555 -
10 Mar 2020 8.620 8.710 8.130 8.430 12,887 -
09 Mar 2020 8.260 8.780 7.790 8.650 30,171 -
06 Mar 2020 8.870 9.380 8.810 9.380 4,267 -
05 Mar 2020 9.260 9.790 8.700 9.790 3,686 -
04 Mar 2020 9.410 9.800 9.410 9.800 4,080 -
03 Mar 2020 9.840 9.840 9.190 9.210 16,072 -
02 Mar 2020 9.170 9.300 9.070 9.130 9,191 -
28 Feb 2020 9.000 9.000 8.360 8.390 6,085 -
27 Feb 2020 9.400 9.430 8.510 8.960 42,302 -
Summary
Current 2 Weeks
(16 Mar 2020 to 27 Mar 2020)
5.625 8.760 4.100 8.070 199,870 -
Previous 2 Weeks
(02 Mar 2020 to 13 Mar 2020)
9.170 9.300 4.100 6.395 115,912 -
4 Weeks from
(31 Jan 2020 to 28 Feb 2020)
10.970 11.068 4.100 8.390 367,360 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.